Apostolia M. Tsimberidou

Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas

1600O Efficacy and safety of IMA203, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in patients with previously treated advanced or metastatic uveal melanoma from a phase I trial

Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma.

Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With <i>ERBB2/3</i> Amplification, Overexpression, or Mutation: Results From the TAPUR Study

LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)

Review of precision cancer medicine: Evolution of the treatment paradigm

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Transcriptomics and solid tumors: The next frontier in precision cancer medicine

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine

Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy

Outcome analysis of Phase I trial patients with metastatic<i>KRAS</i>and/or<i>TP53</i>mutant non-small cell lung cancer

Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience

Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers.

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation

<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial

Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation

Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer

Gene and cell therapy for pancreatic cancer

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing

Analysis of 1,115 Patients Tested for <i>MET</i> Amplification and Therapy Response in the MD Anderson Phase I Clinic

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms